Show/Hide Menu

First MorphoSys-antibody approved
Tremfya® (Guselkumab) available in the USA

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic programs and project advancements in our Annual Report 2016.

More Info

Engineering the medicines 
of tomorrow

Learn how MorphoSys approaches drug development.

More Info

Hematological cancers 
affect adults and children alike.

MorphoSys is developing several blood cancer programs.

More Info

Antibody drugs have transformed the way 
inflammatory and autoimmune diseases are treated today.

MorphoSys is exploring new approaches to continue this success.

More Info

Solid tumors can occur in 
several organs of the human body.

MorphoSys and its partners are working on a broad portfolio of new therapies.

More Info

MorphoSys's vision

MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry.

learn more about the company

07/11/2017
MorphoSys Announces Third Quarter 2017 Results
02/11/2017
MorphoSys Announces Presentation of Clinical Data on Proprietary Blood...
30/10/2017
Dr. Markus Enzelberger Appointed MorphoSys's Chief Scientific Officer
23/10/2017
MorphoSys Receives FDA Breakthrough Therapy Designation for Its Antibody...
27/09/2017
MorphoSys and Galapagos Report First Promising Signs of Clinical Activity...
21/09/2017
MorphoSys Announces That Its Licensee Janssen Has Initiated Two Phase 3...
18/09/2017
MorphoSys Announces that its Licensee Janssen received CHMP Positive...
05/09/2017
MorphoSys Presents Vision for Growth at its Capital Markets Day
03/08/2017
MorphoSys Reports Significant Progress in its Therapeutic Programs in...
21/07/2017
MorphoSys Announces That Its Partner Bayer Reports On Phase 2 Study of...

November 23, 2017
HSBC Healthcare Day
Frankfurt,Germany

conferences

Therapeutic pipeline

MorphoSys has established one of the broadest pipelines in the biopharmaceutical industry.
Pipeline

Media and investors

MorphoSys is driven by the ambition to create the most valuable pipeline of biopharmaceuticals in the industry.
Media and investors

Partnering opportunities

Collaborations are a main component of our strategy. We are open to discuss deal structures where we can contribute to the development of novel drugs in a significant way.
Partnering opportunities

Drug development capabilities

MorphoSys is dedicated to become a fully integrated biopharmaceutical company including late stage clinical development and marketing/co-promotion of its own drugs.
Drug development capabilities

Leading antibody technologies

MorphoSys has made HuCAL and its successor technology Ylanthia into reliable sources of therapeutic antibody candidates.
Leading Antibody Technologies

Proprietary program MOR208

When blood formation leads to cancer: the CD19-antibody MOR208 is currently being evaluated in ALL, CLL and NHL.
MOR208

Antibody backgrounder

Antibodies are essential to life. Today, these molecules are used as therapeutic agents for the treatment of severe diseases.
Antibody Backgrounder

Lighthouse project Gantenerumab

Is being developed by Roche for Alzheimer´s desease.
Gantenerumab